Literature DB >> 17664951

The changing epidemiology of gout.

Edward Roddy1, Weiya Zhang, Michael Doherty.   

Abstract

Gout is one of the most common inflammatory arthritides, which is considered to be a true crystal deposition disorder caused by the formation of monosodium urate crystals in and around joints. A number of epidemiological studies from a diverse range of countries suggest that gout has increased in prevalence and incidence in recent years and that the clinical pattern of gout is becoming more complex. In particular, the greatest increase has been observed in primary gout in older men. Robust epidemiological studies have established risk factors for gout including genetic factors, excess alcohol consumption, purine-rich diet, the metabolic syndrome (obesity, hypertension, hyperlipidemia and insulin resistance), use of diuretics and chronic renal failure. Trends in alcohol use, diet, obesity and the metabolic syndrome in the general population might explain changes in the prevalence and incidence of gout in the community. Osteoarthritis, which is thought to predispose patients to monosodium urate crystal deposition in their joints, is becoming more prevalent as a consequence of increased longevity. In hospital settings, widespread diuretic use, increasing prevalence of end-stage renal failure and the success of organ transplant programmes have led to an increase in clinical complexity. Suboptimal management of gout is likely to have contributed to the rise in the prevalence of clinically overt, symptomatic, chronic gout.

Entities:  

Mesh:

Year:  2007        PMID: 17664951     DOI: 10.1038/ncprheum0556

Source DB:  PubMed          Journal:  Nat Clin Pract Rheumatol        ISSN: 1745-8382


  49 in total

Review 1.  The epidemiology of uric acid and fructose.

Authors:  Young Hee Rho; Yanyan Zhu; Hyon K Choi
Journal:  Semin Nephrol       Date:  2011-09       Impact factor: 5.299

Review 2.  Global epidemiology of gout: prevalence, incidence and risk factors.

Authors:  Chang-Fu Kuo; Matthew J Grainge; Weiya Zhang; Michael Doherty
Journal:  Nat Rev Rheumatol       Date:  2015-07-07       Impact factor: 20.543

3.  Synergic effect in the reduction of serum uric acid level between ethanol extract of Aster glehni and vitamin B6.

Authors:  Eun Hye Han; Mi Kyung Lim; Sang Ho Lee; Hyoung Ja Kim; Dahyun Hwang
Journal:  Food Sci Biotechnol       Date:  2018-06-08       Impact factor: 2.391

Review 4.  Musculoskeletal ultrasonography in the diagnosis of acute crystalline synovitis.

Authors:  Matt Rheinboldt; Courtney Scher
Journal:  Emerg Radiol       Date:  2016-07-20

5.  Gout and Risk of Fracture in Women: A Prospective Cohort Study.

Authors:  Julie M Paik; Seoyoung C Kim; Diane Feskanich; Hyon K Choi; Daniel H Solomon; Gary C Curhan
Journal:  Arthritis Rheumatol       Date:  2017-02       Impact factor: 10.995

6.  Racial differences in gout incidence in a population-based cohort: Atherosclerosis Risk in Communities Study.

Authors:  Janet W Maynard; Mara A McAdams-DeMarco; Andrew Law; Linda Kao; Allan C Gelber; Josef Coresh; Alan N Baer
Journal:  Am J Epidemiol       Date:  2013-12-13       Impact factor: 4.897

7.  Adherence and persistence to urate-lowering therapies in the Irish setting.

Authors:  Bernie McGowan; Kath Bennett; Carmel Silke; Bryan Whelan
Journal:  Clin Rheumatol       Date:  2014-11-20       Impact factor: 2.980

8.  The degree of asymptomatic hyperuricemia and the risk of gout. A retrospective analysis of a large cohort.

Authors:  Hadar Duskin-Bitan; Eytan Cohen; Elad Goldberg; Tzippy Shochat; Amos Levi; Moshe Garty; Ilan Krause
Journal:  Clin Rheumatol       Date:  2014-02-13       Impact factor: 2.980

Review 9.  Treatment Options for Gout.

Authors:  Bettina Engel; Johannes Just; Markus Bleckwenn; Klaus Weckbecker
Journal:  Dtsch Arztebl Int       Date:  2017-03-31       Impact factor: 5.594

10.  The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.

Authors:  Michael A Becker; H Ralph Schumacher; Luis R Espinoza; Alvin F Wells; Patricia MacDonald; Eric Lloyd; Christopher Lademacher
Journal:  Arthritis Res Ther       Date:  2010-04-06       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.